AcroCyte Therapeutics Inc. is dedicated to overcoming common laboratory challenges. Through our R³CE® (Rapid, Reproducible, Rare Cell 3D Expansion) technology, we have established ourselves as experts in 3D culturing, focused particularly on our industry-leading work with CTC (Circulating Tumor Cell). This groundbreaking technology allows us to successfully culture CTCs from a patient’s blood and create personalized 3D cell culture models from virtually any specimen. This innovation eliminates the need for traditional cell lines and animal testing, enabling scientists to conduct research on a platform that is both more authentic and highly efficient. Through our Onco-REAL™ clinical service, we are empowering patients to access truly personalized treatment plans using their own cells.
Individuals seeking employment at AcroCyte Therapeutics are considered without regards to race, color, religion, national origin, age, sex, marital status, ancestry, physical or mental disability, veteran status, gender identity, or sexual orientation.
AcroCyte Therapeutics is closing the gap between laboratory models and patient-specific medicine. Our core technology, the R³CE® platform, is an easy-to-use, FDA-designated Class I, scaffold-free system that rapidly expands minimal patient specimens—like circulating tumor cells, needle biopsies and frozen tissues—into functional 3D organoids in days. This breakthrough powers our commercial Onco-REAL™ clinical service, which provides comprehensive functional analysis from liquid biopsies for timely oncology decisions, while our autologous cell therapy pipeline aims to transform a patient’s own cells into curative solutions. We empower academic, clinical, and industry partners worldwide to leverage the R³CE® platform for novel drug discovery, diagnostics, and regenerative medicine, providing a foundational technology limited only by imagination. AcroCyte is driving a revolution to make these advanced platforms a routine part of clinical practice—accessible, affordable, and impactful for patients worldwide.
View company profile →